Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crises called vaso-occlusive crises (VOC) and chronic inflammation. Activated platelets from SCD patients contribute to both chronic inflammation and painful VOC. Individuals with the HbSC genotype experience anemia and less severe clinical manifestations than those with the HbSS genotype; however, they are at higher risk of venous thromboembolic events, particularly pulmonary embolism.
This study aims to investigate whether sickle cell patients exhibit different thrombin generation profiles as well as distinct platelet activation and aggregation profiles, depending on their SS or SC genotype.
SCD patients with SS or SC
diagnosis of SCD performed by electrophoresis or high-performance liquid chromatography (HPLC) in a reference laboratory for hemoglobinopathies
patients older than 18 years at inclusion
clinically in a steady state at inclusion (no complication in the last month and no transfusion in the three last months)
patients younger than 18 years old
patients with hemoglobinopathy other than SS and SC SCD
patients who have received transfusion therapy or on bleeding therapy for less than three months
patients no affiliated with national social security
Patients with sickle cell disease and the HbSS or HbSC genotype recruited from the participating study centers in Guadeloupe or Bobigny
Cohort
Cross-sectional
Not listed
Endogenous thrombin potential (ETP)
Thrombin generation profiles will be assessed in whole blood, plasma, and platelet-rich plasma. Endogenous thrombin potential will be compared between patients with sickle cell disease and an SS genotype and patients with sickle cell disease and an SC genotype
Lag time of thrombin generation
Thrombin generation will be assessed in whole blood, plasma, and platelet-rich plasma. Lag time will be compared between patients with sickle cell disease and the HbSS genotype and those with the HbSC genotype.
Time to peak thrombin generation
Thrombin generation will be assessed in whole blood, plasma, and platelet-rich plasma. Time to peak will be compared between patients with sickle cell disease and the HbSS genotype and those with the HbSC genotype.
Peak height of thrombin generation
Thrombin generation will be assessed in whole blood, plasma, and platelet-rich plasma. Peak height will be compared between patients with sickle cell disease and the HbSS genotype and those with the HbSC genotype.
Platelet activation profile
Platelet activation profiles will be assessed and compared between patients with sickle cell disease and the HbSS genotype and those with the HbSC genotype.
Click on the lead sponsor to view all of their trials.
Centre Hospitalier Universitaire de la Guadeloupe
Lead sponsor
Hospital Avicenne
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
